

Special Issue

Role of Gut Microbiota in Immune Tolerance and Vaccine Development

Message from the Guest Editor

Immune tolerance refers to a state of active and highly regulated unresponsiveness of the immune system to self-antigens or a specific antigen that can induce an immune response in the body. It plays a crucial role in normal physiology, and deficiencies in tolerance can lead to autoimmune diseases. In recent years, considerable progress has been made in immune tolerance research, particularly in the fields of immunotherapy, immunomodulation, and immune system regulation. However, challenges persist due to incomplete knowledge of the exact mechanisms, a lack of suitable research models, and limited access to clinical data, making it difficult to develop effective treatments for diverse immune tolerance-related disorders. This Special Issue will specifically address (but is not limited to) the following two topics:

- Cellular Aspects of Immune Tolerance in Health and Diseases: The Role of Immune Cell Subtypes and Their Crosstalk.
- The Role of Commensal Microbiota in Immune Tolerance and Vaccines.

We welcome all types of articles, including original research, comprehensive and systematic reviews, brief reports, etc. We eagerly anticipate receiving your contributions.

Guest Editor

Prof. Dr. Sin-Hyeog Im

Department of Life Sciences, Pohang University of Science and Technology (POSTECH), Pohang, Republic of Korea

Deadline for manuscript submissions

31 August 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/195702

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).